GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Checkmate Pharmaceuticals Inc (NAS:CMPI) » Definitions » Pretax Margin %

Checkmate Pharmaceuticals (Checkmate Pharmaceuticals) Pretax Margin % : % (As of Mar. 2022)


View and export this data going back to 2020. Start your Free Trial

What is Checkmate Pharmaceuticals Pretax Margin %?

Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Checkmate Pharmaceuticals's Pre-Tax Income for the three months ended in Mar. 2022 was $-15.87 Mil. Checkmate Pharmaceuticals's Revenue for the three months ended in Mar. 2022 was $0.00 Mil. Therefore, Checkmate Pharmaceuticals's pretax margin for the quarter that ended in Mar. 2022 was %.

The historical rank and industry rank for Checkmate Pharmaceuticals's Pretax Margin % or its related term are showing as below:


CMPI's Pretax Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -154.275
* Ranked among companies with meaningful Pretax Margin % only.

Checkmate Pharmaceuticals Pretax Margin % Historical Data

The historical data trend for Checkmate Pharmaceuticals's Pretax Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Checkmate Pharmaceuticals Pretax Margin % Chart

Checkmate Pharmaceuticals Annual Data
Trend Dec18 Dec19 Dec20 Dec21
Pretax Margin %
- - - -

Checkmate Pharmaceuticals Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22
Pretax Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Checkmate Pharmaceuticals's Pretax Margin %

For the Biotechnology subindustry, Checkmate Pharmaceuticals's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Checkmate Pharmaceuticals's Pretax Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Checkmate Pharmaceuticals's Pretax Margin % distribution charts can be found below:

* The bar in red indicates where Checkmate Pharmaceuticals's Pretax Margin % falls into.



Checkmate Pharmaceuticals Pretax Margin % Calculation

Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.

Checkmate Pharmaceuticals's Pretax Margin for the fiscal year that ended in Dec. 2021 is calculated as

Pretax Margin=Pre-Tax Income (A: Dec. 2021 )/Revenue (A: Dec. 2021 )
=-61.405/0
= %

Checkmate Pharmaceuticals's Pretax Margin for the quarter that ended in Mar. 2022 is calculated as

Pretax Margin=Pre-Tax Income (Q: Mar. 2022 )/Revenue (Q: Mar. 2022 )
=-15.867/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Checkmate Pharmaceuticals  (NAS:CMPI) Pretax Margin % Explanation

The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.

The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.

It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.

The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.


Checkmate Pharmaceuticals Pretax Margin % Related Terms

Thank you for viewing the detailed overview of Checkmate Pharmaceuticals's Pretax Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Checkmate Pharmaceuticals (Checkmate Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
245 Main Street, 2nd Floor, Cambridge, MA, USA, 02142
Checkmate Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing its proprietary technology to harness the power of the immune system to combat cancer.
Executives
Venbio Global Strategic Fund Ii L.p. 10 percent owner 1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158
Alan Bash director, officer: Chief Executive Officer C/O CHECKMATE PAHRMACEUTICALS, INC. 245 MAIN STREET 2ND FLOOR CAMBRIDGE MA 02142
Novo Holdings A/s 10 percent owner TUBORG HAVNEVEJ 19, HELLERUP G7 2900
Jon Marc Wigginton director 9640 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Joy Yan director 10975 NORTH TORREY PINES ROAD, LA JOLLA CA 92037
Arthur M Krieg director, officer: Chief Scientific Officer C/O CHECKMATE PHARMACEUTICALS, INC., 245 MAIN STREET, 2ND FLOOR, CAMBRIDGE MA 02142
Robert Dolski officer: Chief Financial Officer C/O CHECKMATE PHARMACEUTICALS, INC. 245 MAIN STREET, 2ND FLOOR CAMBRIDGE MA 02142
Barry Labinger director, officer: President and CEO C/O CHECKMATE PHARMACEUTICALS, INC., 245 MAIN STREET, 2ND FLOOR, CAMBRIDGE MA 02142
Peter Colabuono director C/O DECHENG CAPITAL 3000 SAND HILL ROAD, BUILDING 2, STE 110 MENLO PARK CA 94025
Oren Isacoff director C/O LONGITUDE CAPITAL 2740 SAND HILL ROAD, 2ND FLOOR MENLO PARK CA 94025
Karen Brennan officer: Chief Operating Officer C/O CHECKMATE PHARMACEUTICALS, INC. 245 MAIN STREET, 2ND FLOOR CAMBRIDGE MA 02142
Kleem Chaudhary officer: Chief Business Officer C/O CHECKMATE PHARMACEUTICALS, INC. 245 MAIN STREET, 2ND FLOOR CAMBRIDGE MA 02142
Venbio Global Strategic Gp Ii, L.p. 10 percent owner 1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158
Venbio Global Strategic Gp Ii, Ltd. 10 percent owner 1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158
Nilesh Kumar director C/O MILESTONE PHARMACEUTICALS, INC., 1111 DR. FREDERIK-PHILIPS BLVD, STE 420, MONTR?AL A8 H4M 2X6

Checkmate Pharmaceuticals (Checkmate Pharmaceuticals) Headlines

From GuruFocus

Novo Holdings A/S Buys 4, Sells 1 in 1st Quarter

By GuruFocus Research GuruFocus Editor 05-18-2022

Top 5 2nd Quarter Trades of venBio Partners LLC

By GuruFocus Research GuruFocus Editor 08-16-2022